Market Eyes LiveElevance Health, Inc. (ELV) Stock Rating & Analysis
MELANY's data-driven read on Elevance Health, Inc. · Hospital & Medical Service Plans.
Elevance Health is among the leading US health insurers, providing medical benefits to 45 million medical members at the end of 2025 through employer, individual, and government-sponsored plans. It is distinguished as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the Blue Cross Blue Shield Association licensee in 14 states.
Why ELV scores 66/100
MELANY scores Elevance Health, Inc. 66/100 by weighing eight factors. Here is how ELV breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 17.7x vs sector 22.0x median
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +15%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for ELV
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Elevance Health, Inc. sits in the Healthcare sector theme, which MELANY currently rates 50/100 for strength. Theme strength feeds ELV's momentum and catalyst factors above.
ELV trade plan (members only)
MELANY has a full position plan for Elevance Health, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates ELV
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Elevance Health, Inc.'s 66/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ELV
Is Elevance Health, Inc. (ELV) a buy?
As of 2026-08-19, MELANY rated Elevance Health, Inc. Favorable with a composite score of 66/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Elevance Health, Inc.'s MELANY score?
Elevance Health, Inc. (ELV) has a MELANY composite score of 66/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the ELV stock rating calculated?
MELANY scores ELV from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Elevance Health, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Elevance Health, Inc. (ELV) Favorable with a composite of 66/100 as of 2026-08-19. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ELV stock price forecast?
MELANY does not publish price targets or forecasts for ELV. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 66/100 across eight factors for Elevance Health, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ELV stock overvalued or undervalued?
MELANY's valuation factor currently reads 69/100 for Elevance Health, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ELV's read.
What price should I buy ELV at?
Rather than chasing the current price, MELANY computes a smart entry zone for ELV: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying ELV stock?
The top risks MELANY currently flags for Elevance Health, Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Elevance Health, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 40/100 for Elevance Health, Inc., and earnings track record, at 100/100. The 66/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ELV stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 68/100 for ELV right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ELV rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-19. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ELV continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
ELV's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.